已收盘 11-20 16:00:00 美东时间
-0.410
-5.61%
Pennant, Iovance and BillionToOne are deeply oversold healthcare stocks, with RSI near 30, potentially offering opportunities despite recent setbacks.
11-20 19:12
Iovance Biotherapeutics upgrades 2026 revenue guidance to $410 million-$420 million. Key technicals, analyst targets, and Amtagvi demand analyzed.
09-30 01:08
Stifel upgraded STAAR Surgical to Buy, while raising its price target, citing China momentum, EVO+ mix and upside to 2026-27 estimates.
09-30 00:01
U.S. stocks fell as job openings declined; oil slid and gold rose. BKYI doubled, SSTI surged, while NIVF plunged 77% and QURE fell 37%.
09-30 00:01
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
2025-11-08 02:04
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
8月19日,美股三大股指期货下跌,截止发稿,道指期货跌0.10%,纳指期货跌0.09%,标普500指数期货跌0.12%。 英特尔盘前涨超6%,软银集团与...
2025-08-19 16:06
Iovance Biotherapeutics授予58名新员工312,660股股票期权,行权价1.98美元,期权在三年内vest。
2025-06-23 20:05
Iovance Biotherapeutics' senior leadership will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 11, 2025 at 1:20 p.m. ET in Miami, FL. The company focuses on developing polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, with Amtagvi® being the first FDA-approved T cell therapy for solid tumors.
2025-06-10 12:45
Iovance Biotherapeutics reported five-year results from its Phase 2 trial of Amtagvi, a TIL therapy for advanced melanoma. The study showed a median overall survival of 13.9 months, 19.7% five-year survival rate, and 31.4% objective response rate. No new adverse events were reported. Amtagvi is the first one-time cell therapy for solid tumors.
2025-05-22 21:31